These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31123759)

  • 21. Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.
    Toda A; Uehara S; Inoue T; Utoh M; Kusama T; Shimizu M; Uno Y; Mogi M; Sasaki E; Yamazaki H
    Xenobiotica; 2018 Jul; 48(7):720-726. PubMed ID: 28686070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strain differences in CYP3A-mediated C-8 hydroxylation (1,3,7-trimethyluric acid formation) of caffeine in Wistar and Dark Agouti rats. Rapid metabolism of caffeine in debrisoquine poor metabolizer model rats.
    Morita K; Maeda Y; Masuda M; Kazusaka A; Imaoka S; Funae Y; Fujita S
    Biochem Pharmacol; 1998 May; 55(9):1405-11. PubMed ID: 10076532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
    Chaobal HN; Kharasch ED
    Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Composite midazolam and 1'-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity.
    Wiebe ST; Meid AD; Mikus G
    J Pharmacokinet Pharmacodyn; 2020 Dec; 47(6):527-542. PubMed ID: 32772302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus).
    Uehara S; Inoue T; Utoh M; Toda A; Shimizu M; Uno Y; Sasaki E; Yamazaki H
    Xenobiotica; 2016; 46(2):163-8. PubMed ID: 26114209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
    Parra-Guillen ZP; Berger PB; Haschke M; Donzelli M; Winogradova D; Pfister B; Früh M; Gillessen S; Krähenbühl S; Kloft C; Joerger M
    Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):309-315. PubMed ID: 28444958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urinary 6β-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach.
    Shin KH; Ahn LY; Choi MH; Moon JY; Lee J; Jang IJ; Yu KS; Cho JY
    AAPS J; 2016 Sep; 18(5):1254-1261. PubMed ID: 27317471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 4β-Hydroxycholesterol as an Endogenous Biomarker for CYP3A Activity: Literature Review and Critical Evaluation.
    Penzak SR; Rojas-Fernandez C
    J Clin Pharmacol; 2019 May; 59(5):611-624. PubMed ID: 30748026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducers.
    Lee J; Yoon SH; Yi S; Kim AH; Kim B; Lee S; Yu KS; Jang IJ; Cho JY
    Drug Metab Pharmacokinet; 2019 Aug; 34(4):247-252. PubMed ID: 31088714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam.
    Wiesinger H; Klein S; Rottmann A; Nowotny B; Riecke K; Gashaw I; Brudny-Klöppel M; Fricke R; Höchel J; Friedrich C
    Clin Pharmacol Ther; 2020 Oct; 108(4):798-807. PubMed ID: 32275771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion.
    Nassar YM; Hohmann N; Michelet R; Gottwalt K; Meid AD; Burhenne J; Huisinga W; Haefeli WE; Mikus G; Kloft C
    Clin Pharmacokinet; 2022 Nov; 61(11):1595-1607. PubMed ID: 36195807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
    Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
    Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
    Bosilkovska M; Samer C; Déglon J; Thomas A; Walder B; Desmeules J; Daali Y
    Basic Clin Pharmacol Toxicol; 2016 Sep; 119(3):284-90. PubMed ID: 27009433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-term fasting alters cytochrome P450-mediated drug metabolism in humans.
    Lammers LA; Achterbergh R; de Vries EM; van Nierop FS; Klümpen HJ; Soeters MR; Boelen A; Romijn JA; Mathôt RA
    Drug Metab Dispos; 2015 Jun; 43(6):819-28. PubMed ID: 25795462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates.
    Sathe AG; Othman AA; Mohamed MF
    J Clin Pharmacol; 2021 Mar; 61(3):307-318. PubMed ID: 32960975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.
    Backman JT; Kivistö KT; Olkkola KT; Neuvonen PJ
    Eur J Clin Pharmacol; 1998 Mar; 54(1):53-8. PubMed ID: 9591931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guidance for Rifampin and Midazolam Dosing Protocols To Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction.
    Kapetas AJ; Sorich MJ; Rodrigues AD; Rowland A
    AAPS J; 2019 Jun; 21(5):78. PubMed ID: 31218462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of midazolam and simvastatin as cytochrome P450 3A probes.
    Chung E; Nafziger AN; Kazierad DJ; Bertino JS
    Clin Pharmacol Ther; 2006 Apr; 79(4):350-61. PubMed ID: 16580903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distribution of Exogenous and Endogenous CYP3A Markers and Related Factors in Healthy Males and Females.
    Lee J; Kim AH; Yi S; Lee S; Yoon SH; Yu KS; Jang IJ; Cho JY
    AAPS J; 2017 Jul; 19(4):1196-1204. PubMed ID: 28523515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.